Apr 01, 2022 7:00am EDT Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission
Feb 11, 2022 8:00am EST Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates
Jan 06, 2022 7:00am EST Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
Jan 06, 2022 7:00am EST Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations
Jan 04, 2022 7:00am EST Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director
Jan 03, 2022 7:00am EST Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication
Nov 12, 2021 8:00am EST Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update
Oct 13, 2021 8:00am EDT Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose
Oct 05, 2021 8:00am EDT Anebulo Pharmaceuticals to Participate in the Benzinga Cannabis Capital Conference in New York City
Sep 22, 2021 4:05pm EDT Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update
